RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...
Biotech firm backs off its focus on oncology research
IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...
TipRanks on MSN4d
ReposiTrak participates in a conference call with Maxim
Analyst Forte holds a conference call with Chairman, President & CEO Fields and CFO Merrill on November 19 hosted by Maxim. ...
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...
Cautious Outlook for IGM Biosciences Amid Delayed Data and Financial Adjustments
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...
manilatimes6d
Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
-- BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor ...
Yahoo Finance6d
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...